Join
Live feed
·
PRReleasevia Quantisnow
AstraZeneca PLC logo

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

ByQuantisnow·Wall Street's wire, on your screen.
AZN· AstraZeneca PLC
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZN (AstraZeneca PLC) and more on Quantisnow.